Every 10-Q that BioRestorative Therapies, Inc. (BRTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BRTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BRTX filings page.
BioRestorative Therapies, Inc. reported first‑quarter 2026 revenue of $23,170, similar to the prior year’s $25,000, with new product sales of its BioX cosmetic line partly offsetting lower royalty income. Operating expenses fell sharply, with research and development at $1.93M and general and administrative at $1.48M, helping narrow the net loss to $2.15M from $5.34M a year earlier.
Results were boosted by a non‑cash gain of $1.22M from remeasuring and reclassifying warrant liabilities to equity. At March 31, 2026, cash and cash equivalents were $3.11M and marketable securities were $0.48M, with working capital of $2.19M. The company completed a Rodman public offering with gross proceeds of $5.0M, providing $4.44M of net financing inflows in the quarter.
Management nonetheless states that recurring losses, negative operating cash flow of $3.81M, and limited resources raise “substantial doubt” about its ability to continue as a going concern without additional capital. The company also received a Nasdaq notice on March 26, 2026 for failing to meet the $1.00 minimum bid price requirement and is evaluating options, including a potential reverse stock split. Material weaknesses in internal control over financial reporting identified in 2025 remain unresolved, though remediation efforts are underway.
BioRestorative Therapies, Inc. (BRTX) filed its Q3 10‑Q, reporting a continuing operating loss as it advances clinical and product initiatives. Q3 revenue was $11,800 (mainly royalties) versus $233,600 a year ago, reflecting timing of cosmetic product orders. Research and development rose to $2,594,750 in the quarter as Phase 2 trial activity increased. Q3 net loss was $3,038,277; for the nine months, revenue was $340,100 and net loss was $11,034,339.
Liquidity tightened: cash was $602,444 and marketable securities were $3,887,383 at September 30, 2025, with working capital of $1,271,781. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern. To raise capital, BRTX sold 965,424 shares under its ATM for $2,011,250 gross in the nine‑month period, and on October 8, 2025 closed a registered offering of 678,125 shares for approximately $1.1 million alongside 508,592 new warrants at a $2.75 exercise price.
Material weaknesses in internal control over financial reporting remained as of September 30, 2025. Shares outstanding were 8,876,242 as of November 11, 2025.
BioRestorative Therapies, Inc. reported a net loss of $7,996,062 for the six months ended June 30, 2025 and a net loss of $2,656,263 for the quarter. Revenue for the three months ended June 30, 2025 was $303,300 versus $89,100 in the prior-year quarter, driven by $300,000 of cosmetic product sales and smaller royalty receipts. Cash and cash equivalents were $1,555,251 and investments in marketable securities were $5,825,685, resulting in working capital of $3,926,572.
The company disclosed substantial doubt about its ability to continue as a going concern, citing ongoing net losses and negative operating cash flow of $5,472,653 for the six months. R&D expense rose to $4,872,782 for six months largely due to Phase 2 clinical trial costs. Management raised net proceeds of $1,938,445 from ATM sales during the period, recorded $2,580,379 of warrant liabilities, and reported material weaknesses in internal control over financial reporting.